Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells

[1]  W. Nichols,et al.  High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer , 1998, Bone Marrow Transplantation.

[2]  G. Gleim,et al.  CD34+CD33- cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  L. Schwartzberg,et al.  Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields. , 1998, Journal of hematotherapy.

[4]  C. Tibaldi,et al.  Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte‐colony stimulating factor administered to patients with metastatic breast carcinoma , 1998, Cancer.

[5]  R. Arranz,et al.  Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone , 1997, Bone Marrow Transplantation.

[6]  J. Hainsworth,et al.  Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer. , 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  P. Pedrazzoli,et al.  Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer. , 1997, British Journal of Cancer.

[8]  D. Linch,et al.  Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Shea.  Mobilization of peripheral blood progenitor cells with paclitaxel-based chemotherapy. , 1997, Seminars in oncology.

[10]  R. Storb,et al.  Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Sutherland,et al.  The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. , 1996, Journal of hematotherapy.

[12]  L. Schwartzberg,et al.  An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. , 1995, Blood.

[13]  R. Storb,et al.  Factors that influence collection and engraftment of autologous peripheral-blood stem cells. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Storb,et al.  Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Offidani,et al.  DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma. , 1995, Bone marrow transplantation.

[16]  P. Bruzzi,et al.  Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5‐fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy , 1994, Cancer.

[17]  R. Storb,et al.  Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG‐CSF): an analysis of factors correlating with the tempo of engraftment after transplantation , 1994, British journal of haematology.

[18]  H. Goldschmidt,et al.  Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. , 1994, Blood.

[19]  G. Rosner,et al.  Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. , 1993, Blood.

[20]  G. Kandel,et al.  Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. , 1992, Bone marrow transplantation.

[21]  L. To,et al.  Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. , 1992, Bone marrow transplantation.

[22]  J. Zucker,et al.  Acceleration of hemopoietic recovery after autologous bone marrow transplantation by low doses of peripheral blood stem cells. , 1991, Bone marrow transplantation.

[23]  P. Conte,et al.  Paclitaxel plus epirubicin in advanced breast cancer. , 1998, Oncology.

[24]  A. Bolton,et al.  Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. , 1992, Bone marrow transplantation.